相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Bruno Vincenzi et al.
CLINICAL CANCER RESEARCH (2022)
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2022)
Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST)-A systematic review
Charlotte Margareta Brinch et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study
Ruolin Liu et al.
CANCER MEDICINE (2022)
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world
Toshirou Nishida et al.
GASTRIC CANCER (2022)
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib
Newton A. C. S. Wong et al.
CANCER GENETICS (2022)
Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
Zhen Liu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
P. G. Casali et al.
ANNALS OF ONCOLOGY (2021)
Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor
Isabelle Vanden Bempt et al.
GENES CHROMOSOMES & CANCER (2021)
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L. Jones et al.
EUROPEAN JOURNAL OF CANCER (2021)
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu et al.
JAMA ONCOLOGY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Defining Tumor Rupture in Gastrointestinal Stromal Tumor
Toshirou Nishida et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
Toto Holmebakk et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate-or High-Risk Primary Gastrointestinal Stromal Tumor The PERSIST-5 Clinical Trial
Chandrajit P. Raut et al.
JAMA ONCOLOGY (2018)
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
Sosipatros A. Boikos et al.
JAMA ONCOLOGY (2016)
Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib
M. J. Wilkinson et al.
BRITISH JOURNAL OF SURGERY (2015)
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
Paolo G. Casali et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
Heikki Joensuu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
Heikki Joensuu et al.
CANCER (2014)
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
Christopher L. Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial
Ronald P. DeMatteo et al.
ANNALS OF SURGERY (2013)
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
Tatsuo Kanda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Gastrointestinal stromal tumour
Heikki Joensuu et al.
LANCET (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Heikki Joensuu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
Heikki Joensuu et al.
LANCET ONCOLOGY (2012)
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs
J. F. Emile et al.
MEDICAL ONCOLOGY (2012)
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes
P. Rutkowski et al.
EJSO (2011)
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
J. Li et al.
EJSO (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
P. Hohenberger et al.
BRITISH JOURNAL OF SURGERY (2010)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
An Evaluation of 2537 Gastrointestinal Stromal Tumors for a Proposed Clinical Staging System
Charles E. Woodall et al.
ARCHIVES OF SURGERY (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
Heikki Joensuu
HUMAN PATHOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations
Abbas Agaimy et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
High incidence of microscopic gastrointestinal stromal tumors in the stomach
Kaori Kawanowa et al.
HUMAN PATHOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gastrointestinal stromal tumors: Pathology and prognosis at different sites
Markku Miettinen et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diagnosis of gastrointestinal stromal tumors: A consensus approach
CDM Fletcher et al.
HUMAN PATHOLOGY (2002)
分享论文
